As we age, we tend to rely on a limited set of connections called the "Default Mode Network" (DMN) which limits our ability to think creatively. However, recent research has shown that psilocybin can increase blood flow to other parts of the brain, helping to create new connections between neurons and promote neuroplasticity. This promotes the brain's ability to think outside the DMN and discover new ways of thinking and experiencing the world, ultimately leading to improved mental health and well-being. In particular, psilocybin has shown promise in breaking free from negative thought patterns that can deepen depression and other mental illnesses.
Link to source
We are designing the best techniques and processes to boost the production of high quality psychoactive compounds.
Challenge
Breaking the Mold: Addressing the Root Causes of Mental Health Conditions with Innovative Treatments
Existing mental health treatments have serious limitations. Standard therapies for depression often cause intolerable side effects, that's one of the reasons why 70% of the patients are non-compliant, and almost 40% of patients do not respond. (Khawam, E., Laurencic, G., & Malone, D. (2006, April). Side effects of antidepressants: An overview. Cleveland Clinic journal of medicine. Retrieved September 18, 2022, link to source). While these treatments may alleviate symptoms, they do not address the root causes of mental health conditions.
1 out of 4 people suffer or will suffer from a diagnosed mental illness.
There are 20 suicide attempts every one death.
Mental illness shortens lifespan by 10-20 years.
Source: World mental health report 2022
Source: World mental health report 2022
Approach
Unlocking the Power of Psilocybin: Break Free from Negative Thoughts and Enhance Your Mental Health
Indicators
Ark Invest. Link to source
Antidepressants
Psychedelics
40%-50%
After a year of therapy, almost half of the antidepressant users relapse.
20%-30%
of psilocybin users relapse.
Therapy kind
Symptom mitigator
Therapy kind
Adresses root-cause problem
Administration
Daily dosage
Administration
1-2 dose/s a year
Ark Invest. Link to source
Strategy
Expanding Horizons: Our Psychedelic Portfolio
We already started with psilocybin. We are focusing on providing a seamless B2B client experience. Our streamlined production process ensures high-quality, cost-effective, and scalable production for specific client needs and locations.
Psilocybin
Bufotenine
DMT
Ibogaine
5-Meo-DMT
Technology
Our focus is on the process and (B2B) client experience
Expression on GMOs
Our team is working on the genetic modification of selected microorganisms (GMOs) to express the enzymatic machinery necessary for the production of psilocybin/tryptamine compound.
.png)
Biosynthesis
Our unique enzymatic strategy through GMOs allows us to produce high-quality psilocybin directly from a bioreactor. This process illustrates a departure from traditional synthetic methods as we use cells or their isolated enzymes to catalyze reactions.
Our process is
Stable
Scalable
Sustainable
Our Process
Our innovative design is based on producing tryptamine derivatives in a bioreactor using biosynthesis processes. The process consists of only three steps, followed by extraction and purification in flow systems. This method is highly scalable, easy, and fast to purify, resulting in more than 50% cost reduction.
Leading the way in new therapies: EYWA’s team
.png)
Thanks for trusting us
Join our team to make a difference
We are on linkedinThere are currently no open positions available but feel free to reach us out through our contact form if you believe that you can fit our mission!
